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Abstract MammaPrint is an FDA-cleared microarray-
based test that uses expression levels of the 70 Mam-
maPrint genes to assess distant recurrence risk in early-
stage breast cancer. The prospective RASTER study
proved that MammaPrint Low Risk patients can safely
forgo chemotherapy, which is further subject of the
prospective randomized MINDACT trial. While Mam-
maPrint diagnostic results are obtained from mini-arrays,
clinical trials may be performed on whole-genome arrays.
Here we demonstrate the equivalence and reproducibility
of the MammaPrint test. MammaPrint indices were col-
lected for breast cancer samples: (i) on both customized
certified array types (n = 1,897 sample pairs), (ii) with
matched fresh and FFPE tissues (n = 552 sample pairs),
iii) for control samples replicated over a period of 10 years
(n = 11,333), and iv) repeated measurements (n = 280).
The array type indicated a near perfect Pearson correlation
of 0.99 (95 % CI: 0.989–0.991). Paired fresh and FFPE
samples showed an excellent Pearson correlation of 0.93
(95 % CI 0.92–0.94), in spite of the variability introduced
by intratumoral tissue heterogeneity. Control samples
showed high consistency over 10 year’s time (overall
reproducibility of 97.4 %). Precision and repeatability are
overall 98.2 and 98.3 %, respectively. Results confirm that
the combination of the near perfect correlation between
array types, excellent equivalence between tissue types,
and a very high stability, precision, and repeatability
demonstrate that results from clinical trials (such as
MINDACT and I-SPY 2) are equivalent to current
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MammaPrint FFPE and fresh diagnostics, and can be used
interchangeably.
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Abbreviations
CLIA Clinical Laboratory Improvement Amendments
FDA US Food and Drug Administration
FFPE Formalin-fixed paraffin-embedded
IDE Investigational device exempt
IVD In vitro diagnostic
LTD Laboratory developed test
Introduction
The use of multigene diagnostic testing to guide cancer
treatment has increased dramatically, since the clinical
introduction of the first US Food and Drug Administration
(FDA)-cleared multigene diagnostic signature Mam-
maPrint [1]. These types of genomic tests interrogate gene
expression levels in tissues to give information about the
disease state and/or prognosis, and have led to new diag-
nostic approaches that are recognized by international
clinical guidelines [2, 3]. MammaPrint determines the
expression of 70 signature genes and helps guide physi-
cians to make adjuvant treatment decisions for early-stage
breast cancer patients [4, 5]. The test is suitable for both
fresh or fresh frozen (fresh) tissues and formalin-fixed
paraffin-embedded (FFPE) tissues [4, 6, 7]. MammaPrint is
part of Agendia’s In Vitro Diagnostic (IVD) Test Suite that
also includes BluePrint, which reveals breast cancer sub-
type [8].
MammaPrint was developed and validated based on
fresh frozen tissues and cleared by the FDA [1, 4, 9, 10].
However, for diagnostic purposes, shipment of frozen tis-
sue is not always easily implemented in community hos-
pitals. Therefore, RNAretain (for room temperature sample
stabilization during shipment) was validated, FDA-cleared
and implemented [11, 12] and subsequently, MammaPrint
was validated and cleared for use of FFPE tissues [6, 13].
To date, MammaPrint is one of the two (MammaPrint and
Prosigna [14]) FDA-cleared [15] clinically implemented
breast cancer multigene expression tests with 6 clearances,
and obtained the EU IVD CE mark, for both fresh and
FFPE tissues [1, 11, 13, 16–18]. Claims on current diag-
nostic clinical utility include its well-established prognostic
value for metastasis risk assessment for early-stage breast
cancer patients [5, 9, 10, 19–22].
Since 2004, MammaPrint has been used for over 90,000
patients to determine the patient’s distant recurrence risk.
The activity of the 70 signature genes is compiled in an
index that is used to establish the qualitative MammaPrint
results: Low Risk or High Risk for distant recurrence.
Designated clinically low risk patients with positive hor-
monal receptor status could well be treated by hormonal
therapy in the adjuvant setting [3], while clinically high
risk patients are more suited to receive a combination of
chemotherapy and hormonal therapy in an (neo-) adjuvant
setting [3]. Clinical studies have shown MammaPrint’s
clinical prognostic value in lymph-node negative [10, 22]
and lymph-node positive [19] breast cancer, for women
diagnosed at all ages [21], and irrespective of pathological
grade [9], estrogen receptor status or HER2 expression
[20]. The RASTER study [12] provided the first prospec-
tive evidence of clinical utility for MammaPrint. It showed
a 98.9 % 5-year metastasis-free survival for patients that
were clinically high risk, based on standard clinical
parameters, but who chose not to receive adjuvant
chemotherapy based on their MammaPrint Low Risk status
[5]. These study results indicated that these patients could
safely forgo chemotherapy [23]. Confirmation of Mam-
maPrint’s prognostic value is expected in 2016, when
results are projected for the large European Organization
for Treatment and Cancer (EORTC) prospective random-
ized clinical MINDACT trial (EORTC 10041; BIG 3-04)
[24–26].
MammaPrint results can be obtained from both cus-
tomized mini-arrays and from customized whole-genome
arrays. Both array types contain multiple replicates of the
70 signature probes complemented with an identical large
set of replicated normalization and control probes. Diag-
nostic MammaPrint results are generally obtained using
customized mini-arrays (also referred to as 8-pack arrays),
accommodating 8 individual samples per array [4]. In large
clinical trials like MINDACT [26] and I-SPY 2 [27],
MammaPrint expression analysis was performed on whole-
genome arrays containing over 32,000 unique probes per
array. This array type is currently used in the I-SPY 2 trial
with a MammaPrint FDA Investigational Device Exempt
(IDE) status. For MammaPrint diagnostic use in Europe,
both the customized mini-array and the customized whole-
genome array hold an IVD EU directive CE mark. The use
of whole-genome arrays allows providing MammaPrint
results to clinical trial participants alongside enabling full-
genome analysis for the early development of new gene
expression signatures. For the MINDACT trial, this resul-
ted in an unprecedented dataset representing almost 6700
early-stage breast cancer patients.
The aim of the current study is to evaluate the equiva-
lence and robustness of the MammaPrint test in different
settings. Microarray types [28, 29] as well as tissue
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preservation techniques [30] have been known to poten-
tially influence array expression profiles in general. We,
therefore, evaluated the agreement of MammaPrint indices
between the customized mini-arrays and whole-genome
arrays for 1897 array sample pairs and between fresh and
FFPE tissues in 552 tissue sample pairs, and assessed
reproducibility of[11,000 control samples over the last 10




MammaPrint indices as reported were collected for all
patient tumor samples processed for which the sample was
hybridized to both a customizedmini-array and a customized
whole-genome array (n = 1897 sample pairs, totaling 3,794
sample hybridizations, 2005–2015), or for which samples
with both fresh (fresh frozen or RNAretain) and FFPE tissues
were hybridized to individual arrays (n = 552 totaling 1104
sample hybridizations (2011–2015)). Data for the fresh
versus FFPE comparison include the RASTER series [12]
and a data series described previously by Sapino et al. [6].
Clinicopathological data and clinical outcome data were
available for those 345 of the RASTER patients with mat-
ched samples of fresh and FFPE tissues [5, 12]. Additionally,
for assessing the analytical performance of MammaPrint,
indices were collected for fresh and FFPE samples repre-
senting MammaPrint High Risk and Low Risk samples. A
total of 7 samples were measured for 20 days in duplicate,
totaling to 280 measurements.
For this study, only data and not samples were collected.
All data and analyses used or performed for this study
comply with the current ethical laws of the Netherlands.
All patient sample data were anonymized in accordance
with national ethical guidelines (‘‘Code for Proper Sec-
ondary Use of Human Tissues,’’ Dutch Federation of
Medical Scientific Societies), study samples belonging to
the used data had Institutional Review Board approvals.
For this type of study, formal consent is not required.
Control samples
High Risk and Low Risk MammaPrint control samples are
standardly used as technical and experimental controls
within each batch run of samples. Data from MammaPrint
control samples, each composed of a pool of clinically
representative breast cancer tumors, are continuously
monitored in the clinical diagnostic setting, and were
available for stability assessment of MammaPrint test
indices in this study [4, 6, 31]. All control samples were
processed at one of Agendia’s core laboratory facilities in
Amsterdam (The Netherlands) or Huntington Beach/Irvine
(California, US) from August 2005 until March 2015,
totaling n = 11,333 data points for analyses.
Statistical analysis
Analyses and visualization of data were performed in R (ver-
sion 3.1.1) and RStudio (version 0.98.994). All samples had
passed standard diagnostic quality control criteria [4, 6, 31].
Equivalence of MammaPrint indices was determined by
the Pearson correlation for assessment of the degree of
linear correlation, and a Passing-Bablok regression analysis
to obtain the regression equation. Bland–Altman plots were
used to visually examine the existence of any constant bias
in the difference of measurements between paired samples.
The Bland–Altman analysis allows visual identification of
any proportional error (if data points show an angled linear
association), systemic error (if the horizontal mean differ-
ence line of the data points is shifted parallel away from
zero), or dependence of a method on the magnitude of
measurements (if data points show an association that
widens or narrows from left to right).
Clinicopathological data and clinical outcome data of
the 345 patient samples were analyzed using the statistical
package SPSS 22.0 for Windows (SPSS Inc, Chicago, US).
Survival analyses were performed to compare clinical
performance of fresh and FFPE tissues. Kaplan–Meier
analyses were used to compare the survival distributions of
MammaPrint for fresh and FFPE for distant metastasis as
first event (DMF) and distant recurrence-free interval
(DRFI). DMF was defined as the time from surgery until
the diagnosis of a distant metastasis as first event. For
DMF, patients who present with a local recurrence,
regional recurrence, or second primary tumor before the
diagnosis of a distant metastasis were censored at such
event, at death or at the end of follow-up. DRFI was
defined as the time from surgery until the diagnosis of a
first distant metastasis or breast cancer-related death.
Reproducibility of the MammaPrint test was tested by
evaluating diagnostic controls over a period of 10 years to
assess nearly all sources of variation in n = 11,333 sam-
ples. Reproducibility was measured in terms of the relative
stability, calculated as 100 minus the relative standard
deviation, where the standard deviation was measured as a
percentile of the total MammaPrint range [31]. To enable
assessment of MammaPrint stability of repeated control
sample measurements over time and independent of control
sample, MammaPrint indices were centered on their indi-
vidual sample mean per RNA reference type.
The analytical performance of the current MammaPrint
fresh and FFPPE versions was assessed in a precision
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evaluation experiment according to the EP2-A5 docu-
mentation [32], as described by Delahaye et al. [31]. This
analysis included precision and repeatability assessment of
MammaPrint High Risk and Low Risk samples. Precision
was determined by calculating the relative precision for
repeated measurements of High Risk and Low Risk breast
cancer samples over a period of 20 days. Repeatability was
determined by calculating the relative stability between
duplicate runs of the repeated measurements performed
each day. Both the relative stability and the relative pre-
cision are calculated as 100 minus the relative standard
deviation.
Results
Equivalence of MammaPrint indices for mini-arrays
versus whole-genome arrays
In large clinical trials, whole-genome gene expression
arrays are used at times to enable discovery of expression
signatures associated with a clinical endpoint of interest,
alongside certified clinical diagnostic tests such as Mam-
maPrint. To demonstrate the equivalence of FDA-cleared,
EU IVD-certified MammaPrint between customized mini-
array and customized whole-genome array types, we
assessed the agreement between MammaPrint index values
of breast cancer tissues hybridized to both array types
(Fig. 1). Equivalence was measured using a set of 1897
samples with matching mini- and whole-genome arrays,
spanning the MammaPrint index range generally seen in
diagnostics. MammaPrint indices generated using the
customized whole-genome array showed an almost perfect
correlation with the matching indices for the diagnostic
arrays (r = 0.99, 95 % CI 0.989–0.991). Figure 1 shows
the scatterplot of the indices showing a tight clustering
around the 45 line of perfect correlation. This was con-
firmed by the Passing and Bablok regression analysis
(y = 0.002 ? 1.00x) and a Bland and Altman analysis
showing no bias in the association of MammaPrint indices
between mini-array and whole-genome array types (Online
Resource 1).
In conclusion, comparison of 1897 mini-array versus
whole-genome array sample pairs showed equivalence and
robustness of MammaPrint results between the different
arrays types both containing the 70 diagnostic Mam-
maPrint probes.
Equivalence of MammaPrint indices from fresh
versus formalin-fixed paraffin-embedded tissues
The MammaPrint test, originally developed on fresh tis-
sues, was translated to FFPE to facilitate diagnostics and
subsequently cleared by the FDA in 2015 [6, 13]. Tissue
preservation techniques have been known to generally
influence array expression profiles [30]. Here, we extend
our comparison study to examine the compatibility
between MammaPrint indices results on fresh versus FFPE
samples in a dataset of 552 sample pairs (Fig. 2). The
Pearson correlation of the MammaPrint indices calculated
for the fresh and FFPE tissues was 0.93 (95 % CI
0.92–0.94). This is an excellent correlation given the data
are naturally influenced by the heterogeneity within the
tumor tissue and potential difference in tissue preservation
techniques. This was confirmed by the Passing and Bablok
regression analysis (y = -0.076 ? 1.05x) and a Bland and
Altman analysis showing no relevant bias in the association
of MammaPrint indices between fresh and FFPE tissue
types (Online Resource 1). These results confirm the very
high correlation between fresh and FFPE, which is in line
with the MammaPrint FFPE FDA clearance [15].
In summary, comparison of 552 fresh versus FFPE
sample pairs showed very high comparability of Mam-
maPrint indices between the tissue preservation techniques.
Impact of tissue preservation technique
on MammaPrint patient survival prediction
Highly correlated continuous values may result in a lower
concordance when these continuous variables are presented
as binary categories. In particular, samples with a result
close to a classification threshold that have a very small
difference between two measurements may still result in a
switch in binary outcome. Therefore, samples in diagnos-
tics with an index close to the MammaPrint classification
threshold (area predefined) are tested multiple times to
Fig. 1 Equivalence of MammaPrint between customized mini- and
whole-genome array types. Scatterplot showing equivalence of
MammaPrint indices between customized mini-microarray used in
diagnostics (x-axis) and customized whole-genome array (y-axis)
hybridizations. Each dot represents a single female breast cancer
sample for which labeled RNA was hybridized to both array types
(n = 1897 sample pairs)
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increase measurement precision. We assessed and com-
pared the clinical performance of MammaPrint in a retro-
spective setting to investigate the overall clinical effect of
samples that have MammaPrint results generated from both
fresh and FFPE tissues.
Survival analysis for DMF and DRFI was performed for
MammaPrint High Risk and Low Risk in a dataset of 345
early-stage breast cancer patients for which matching fresh
and FFPE tissues were available (Fig. 3). The Kaplan–
Meier curves (Fig. 3) for DMF and DRFI are similar
between fresh and FFPE results. Moreover, 5-year survival
rates for both the Low Risk and High Risk patients groups
were comparable between fresh and FFPE as shown in
Table 1.
Summarizing, we showed clinical equivalence for
MammaPrint results from fresh and FFPE tissues.
MammaPrint stability over time
To assess the stability of the MammaPrint test over time,
we investigated the reproducibility of MammaPrint results
in a large pool of control samples spanning a 10-year
period, and investigated the precision and repeatability of
MammaPrint High Risk and Low Risk samples.
Control samples are used standardly as technical and
experimental controls within each batch run of samples to
monitor the quality. A minimum of two control samples are
processed with each batch run, covering both binary results
of the MammaPrint test. Stability of MammaPrint indices
was assessed over a 10-year time period using the control
samples of Agendia’s MammaPrint quality control
monitoring system (n = 11,333). Three different fresh Low
Risk controls, five different fresh High Risk controls, one
FFPE Low Risk control and two different FFPE High Risk
controls were used during this period of 10 years. Once a
control sample is near depletion, a new control sample is
created to replace it. Subsequently, both controls are used
simultaneously for at least 20 measurements to assure the
quality of the new control sample. Because each control
sample has a different expected MammaPrint index, indices
were centered on their individual sample mean to enable
stability assessment over time independent of control sam-
ple. A data series of Low Risk and High Risk control sample
measurements for both fresh and FFPE specimen types was
available for stability assessment: n = 2494 fresh LowRisk,
n = 4072 fresh High Risk controls (Fig. 4a), and n = 1639
FFPE Low Risk, n = 3128 FFPE High Risk controls
(Fig. 4b). MammaPrint indices of these control samples
were plotted over time (10 years) in a run-sequence plot
(Fig. 4), demonstrating high stability and reproducibility as
the same result is generated regardless of scanner used,
operator, lot, or day. The mean difference of the Mam-
maPrint indices from the sample mean was 0.0295 (95 % CI
0.0289–0.0301) and 0.0477 (95 % CI 0.0466–0.0488) for
fresh and FFPE controls, respectively. The standard devia-
tion was 0.0415 for fresh and 0.0619 for FFPE. Repro-
ducibility is given as 100 minus the relative standard
deviation, 97.9 % for fresh and 96.9 % FFPE, resulting in
overall reproducibility of 97.4 %, which is very close to the
original reported value [6, 31].
While the reproducibility of the MammaPrint test was
assessed in control samples consisting of pooled RNA of
breast cancer samples, the analytical performance of the
MammaPrint test was determined using (non-pooled)
individual samples. The analytical performance of Mam-
maPrint fresh and FFPE in this study was assessed by
determining the precision and repeatability in samples
representing MammaPrint High Risk and Low Risk results
that were measured twice per day for 20 days, totaling 280
measurements. The overall precision was 98.2 % (99.0 %
for fresh and 97.3 % for FFPE), while repeatability overall
was 98.3 % (99.0 % for fresh and 97.6 % for FFPE).
In summary, data on diagnostic control samples of
Agendia’s quality control monitoring system, covering
10 years, and repeated measurements of samples show that
the MammaPrint test for both fresh and FFPE is constant
over time.
Discussion
The study results show that MammaPrint is a robust and
stable test, regardless of whether the used array type is a
customized mini-array or customized whole-genome array,
Fig. 2 Equivalence of MammaPrint between matched fresh and
FFPE tissue samples. Equivalence was assessed on tumor samples for
which both the FFPE and fresh tumor samples were analyzed. The
data are naturally influenced by intrinsic tissue heterogeneity, over
5 % difference in MammaPrint results can be attributed to hetero-
geneity within the tumor [6, 31]. Each dot represents a single female
breast cancer sample for which RNA derived from fresh and FFPE
tissues was hybridized twice to either a customized mini or
customized whole-genome microarray (n = 552 hybridization pairs)
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or the specimen type is fresh or FFPE. The excellent
reproducibility of MammaPrint indices of control samples
over the last 10 years and the excellent precision and
repeatability of MammaPrint High Risk and Low Risk
samples is further testament to the quality and robustness
of the MammaPrint test.
A major strength of our current study lies in the large
sample size. Almost 2000 sample pairs demonstrated a
near perfect agreement in MammaPrint index values
between mini and whole-genome array types. Addition-
ally, 552 sample pairs (with clinical data available for 345
sample pairs) contributed to the comparison between fresh
and FFPE MammaPrint results, with the results indicating
excellent agreement. Assessment of the[11,000 control
samples exemplifies the high stability of the MammaPrint
results over time. Finally, robustness was shown in the
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Fig. 3 Equivalence in Survival
data for DMF and DRFI in 345
patients with matched fresh and
FFPE samples. Kaplan–Meier
curves were plotted for DRFI
and DMF to assess the clinical
equivalence of MammaPrint
Low Risk (green lines) and
High Risk (red lines) between
matched fresh and FFPE in a
series of 345 early-stage breast
cancer patients. The majority of
the patients that were classified
as High Risk were treated in an
adjuvant setting. The majority
of patients classified as Low
Risk were untreated. Log Rank
(Mantel-Cox) p values are
indicated per analysis
Table 1 Equivalence in
Survival percentages for DMF
and DRFI in 345 patients with
matched fresh and FFPE
samples
MammaPrint (Fresh tissues) MammaPrint (FFPE tissues)
% 95 % CI % 95 % CI
DMF
Low risk 97.6 95.2–100 98.7 96.9–100
High risk 90.7 86.0–95.4 89.9 85.2–94.6
DRFI
Low risk 97.6 95.2–100 98.7 96.9–100
High risk 89.1 84.0–94.2 88.3 83.2–93.4
Survival percentages, at 5 years after surgery, for DMF and DRFI for MammaPrint fresh and FFPE results.
Survival percentages and their 95 % confidence interval are given for the Low Risk and High Risk groups,
separately
DMF distant metastasis as first event; DRFI distant recurrence-free interval; FFPE formalin-fixed paraffin-
embedded; %, survival percentage at 5 years since surgery; 95 % CI, ninety-five percent confidence
interval
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Other IVD multigene assays are currently available for
early breast cancer patients, including the Prosigna Breast
Cancer Prognostic Gene Signature Assay (ProSigna, Seat-
tle, WA, USA [14]), OncotypeDx Breast Cancer Assay
(Genomic Health, Redwood City, CA, USA [33]), Breast
Cancer Index (BioTheranostics, San Diego, CA, USA
[34]), and EndoPredict test (Sividon Diagnostics GmbH,
Koln, Germany [35]). These assays are dedicated to FFPE
breast cancer tissues and based on either microarray or
(RT)-(q)PCR technology. IVD tests, like MammaPrint,
need to be accurate, reliable, and clinically meaningful.
Regulation under Clinical Laboratory Improvement
Amendments (CLIA) is the first crucial step for quality
control related to laboratories and personnel. To ensure full
patient safety and quality control of IVD tests, including
the group of laboratory developed test (LDTs), adhering to
FDA regulation is essential [36]. For diagnostic tests per-
formed in the EU the equivalent regulatory oversight is the
EU IVD CE mark and laboratory ISO-certification,
requirements for which MammaPrint obtained regulatory
certification as well. MammaPrint was the first of only two
(MammaPrint and Prosigna Breast Cancer Prognostic Gene
Signature Assay) of the above described multigene
signatures to obtain IVD CE mark and FDA clearance, for
which it was required to demonstrate both analytical
validity and clinical validity [36]. Moreover, MammaPrint
is the first multigene classifier to publicly demonstrate such
robust stability over time. Of note is that MammaPrint is
independent of clinical factors, whereas the Prosigna gene
signature assay is a combination of gene expression
assessment (PAM50) and clinical factors (tumor size and
proliferation score). MammaPrint diagnostic testing,
including array types, is performed per FDA IVD 510 K
clearance, or FDA Investigational Device Exempt status
(IDE) for tests in the US, and EU IVD CE mark, whichever
is required based on the quality regulatory oversight in
respective countries.
Large clinical studies featuring IVDs based on
microarray technology often use whole-genome arrays to
enable whole-genome analyses in relation to clinical end-
points of interest alongside the IVD results. This is a major
advantage of the utility of microarrays for IVDs over RT-
PCR. When diagnostics is generally performed on dedi-
cated microarrays, it is of critical importance to demon-
strate equivalence between the different array types. For
MammaPrint, we demonstrated that based on the near
Fig. 4 Stability of MammaPrint indices of diagnostic control sam-
ples over time. Stability of MammaPrint indices of MammaPrint High
Risk and MammaPrint Low Risk control samples measured over a
period of 10 years (2005–2015) for fresh (a) and 5 years (2011–2015)
for FFPE (b) separately. To enable comparison of the different control
samples for Low Risk and High Risk, MammaPrint indices were
centered on their individual sample means (see ‘‘Methods’’ section)
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perfect agreement (r = 0.99) between different array types,
study results based on whole-genome arrays similarly
apply to the current diagnostic setting.
Previously, special arrangements were made by physi-
cians to obtain a fresh tissue specimen during surgery for
MammaPrint. To broaden utility, we translated Mam-
maPrint to FFPE, thereby enabling the use of FFPE tissues
and facilitating the decision of applying a MammaPrint test
even after surgery of the primary tumor. A comparison
between fresh and FFPE tissues of the same sample is
naturally influenced by intrinsic intratumoral heterogeneity
and differences in tissue preservation techniques [30] that
are together fully accounting for the observed deviations. A
difference of 5 % in MammaPrint binary result can be
attributed to these phenomena [6, 31]. Despite this influ-
ence, comparison between fresh and FFPE demonstrated
very high agreement (r = 0.93) in both MammaPrint Index
values [6] and visualized clinical outcome prognosis,
affirming previously described results [13]. Taken together,
study results of large clinical studies featuring the 70-gene
profile MammaPrint, in particular, the MINDACT trial
whose level 1a evidence results will be available in 2016,
can be interpreted and transposed to the current diagnostic
setting based on FFPE tissues without any reservations.
In summary, study results confirm that MammaPrint
indices generated from customized mini-arrays show near
perfect agreement to MammaPrint indices obtained from
customized whole-genome arrays. Additionally, Mam-
maPrint for fresh and FFPE tissues are robust, equivalent,
and stable tests (also at the clinical level) in spite of
influences by tissue heterogeneity and tissue preservation
techniques. Finally, stability assessment confirmed a very
high reproducibility, precision, and repeatability of the
MammaPrint test over time. This combination of high
equivalence between different array types, between tissue
types, and high stability over time demonstrates that results
from clinical trials like MINDACT and I-SPY 2 are similar
to the current MammaPrint FFPE and fresh diagnostics and
can be used interchangeably.
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